Human papillomavirus infection

BD Launches Fully Automated, High-Throughput Infectious Disease Molecular Diagnostic Platform in the U.S.

Retrieved on: 
星期四, 五月 12, 2022
Risk, DNA, STI, Disease, Company, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Urine, CT, BD, Patient, Solution, Health, Trichomonas, CE, COVID-19, Collection, Becton, FDA, Efficiency, GC, Female, Trichomonas vaginalis, Pregnancy, Neisseria gonorrhoeae, Safety, Organization, MX, BDX, Human papillomavirus infection, Therapy, LinkedIn, Twitter, HIV, Becton, Dickinson and Company headquarters, GX, Male, Laboratory, NYSE, Chlamydia trachomatis, HPV, Pharmaceutical industry, Medical device, Chlamydia

FRANKLIN LAKES, N.J., May 12, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. launch of its new, fully automated, high-throughput infectious disease molecular diagnostics platform.

Key Points: 
  • FRANKLIN LAKES, N.J., May 12, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. launch of its new, fully automated, high-throughput infectious disease molecular diagnostics platform.
  • With 510(k) clearance from the U.S. Food and Drug Administration (FDA), the new BD COR MX instrument is a new analytic instrument option for the BD COR System.
  • The BD COR MX/PX System integrates and automates the complete molecular laboratory workflow, from sample processing to diagnostic test result for large, high-throughput labs.
  • The BD COR System is fully automated, modular, and scalable instrument, designed to address multiple needs within laboratories to handle expanding molecular testing volumes.

binx health and Wellfleet Partner to Broaden Equitable Access to HPV Screening Through the binx everywhere Care Platform

Retrieved on: 
星期三, 五月 4, 2022
General Health, FDA, Infectious Diseases, Other Health, Health, Workplace, United States Department of Health and Human Services, Head, Jean-Louis Vincent, Binx, Department, Immune system, Insurance, Accident, LLC, University, Neck, Superior, Company, Berkshire Hathaway, HHS, Â, Male, Partnership, Infection, Risk, FDA, Cancer, Chlamydia, Cancer Breakthroughs 2020, MD, Health, Cervical cancer, Gonorrhea, Female, MBA, HPV, Vaccination, Solution, CEO, Technology, Collection, COVID-19 policy of the Joe Biden administration, Human papillomavirus infection, Multimedia, Vaccine, Pharmaceutical industry

binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, has partnered with student health insurer Wellfleet to broaden access to human papillomavirus (HPV) testing through convenient, at-home sample collection.

Key Points: 
  • binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, has partnered with student health insurer Wellfleet to broaden access to human papillomavirus (HPV) testing through convenient, at-home sample collection.
  • The Cancer Moonshot Fact Sheet recognizes that facilitating HPV screening outside the clinic (e.g., through at-home and mobile screening) is critical to reducing barriers and ensuring equitable access.
  • It is gratifying to be shoulder-to-shoulder with an organization as committed to student health as Wellfleet, said Jeff Luber, binx health President and CEO.
  • Wellfleet is the marketing name used to refer to the insurance and administrative operations of Wellfleet Insurance Company, Wellfleet New York Insurance Company, and Wellfleet Group, LLC.

SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors

Retrieved on: 
星期三, 四月 27, 2022
Oncology, Health, FDA, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Publication, U.S. Securities and Exchange Commission, NYSE, Virus, Immune tolerance, Cell, SQZ, Confidentiality, Cancer, E7, Patient, Human papillomavirus infection, FDA, Risk, DLT, HPV, Fast track (FDA), Private Securities Litigation Reform Act, COVID-19, Degenerative disease, Food, Vulva, ESMO, APC, Penis, Autoimmunity, Therapy, Annual report, Woman, CDC, E6, Research, Doctor of Philosophy, Canadian International Council, Review, Center, International Journal of Cancer, Centers for Disease Control and Prevention, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Infection, Safety, Man, Pharmaceutical industry, Vaccine

SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the companys lead cell therapy candidate, SQZ-PBMC-HPV, for the treatment of HPV16+ advanced or metastatic solid tumors.

Key Points: 
  • SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the companys lead cell therapy candidate, SQZ-PBMC-HPV, for the treatment of HPV16+ advanced or metastatic solid tumors.
  • We are thrilled to receive FDA Fast Track Designation for our SQZ Antigen Presenting Cells product candidate, said Armon Sharei, Ph.D., Chief Executive Officer and Founder at SQZ Biotechnologies.
  • The FDA Fast Track program can potentially expedite future review processes and accelerate the registrational path for SQZ-PBMC-HPV.
  • SQZ-PBMC-HPV is being evaluated in a Phase 1/2 clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors.

Enzo Biochem Announces New York State Department of Health Approval of HPV Molecular Diagnostic Test

Retrieved on: 
星期二, 四月 19, 2022
Patent, Human papillomavirus infection, New York State Department of Health, Trichomonas, Achievement, LDT, Cervical cancer, Vertically transmitted infection, Mycoplasma, DOH, American Cancer Society, GLOBE, Risk, ENZ, Maritime Transportation Security Act of 2002, Infection, HPV, Securities Exchange Act of 1934, Intellectual property, Mycoplasmataceae, Review, BV, Company, Neisseria gonorrhoeae, Trichomonas vaginalis, Chlamydia trachomatis, NYSE, Candida, FDA, Securities Act of 1933, Health, Vaccine

NEW YORK, NY, April 19, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (Enzo or the Company), a leading biosciences and diagnostics company, announced that it has received approval from the New York State Department of Health (DOH) for its AMPIPROBE HPV test.

Key Points: 
  • NEW YORK, NY, April 19, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (Enzo or the Company), a leading biosciences and diagnostics company, announced that it has received approval from the New York State Department of Health (DOH) for its AMPIPROBE HPV test.
  • The AMPIPROBE HPV test is Enzos PCR-based test designed to detect 14 high-risk human papillomavirus (HPV) variants.
  • HPV testing is part of Enzos focus on womens health and oncology and leverages the Companys long history in HPV detection.
  • Almost all cervical cancers are linked to infection with high-risk HPV, an extremely common virus transmitted through sexual contact.

Microbix Presenting HPV Product Results at EUROGIN

Retrieved on: 
星期五, 四月 8, 2022
Adoption, Company, Cancer, Medical device, Organization, TGA, BD, U.S. FDA, Sale, OTCQX, CE, HPV, ISO 9001, IVD, Patient, PCR, Pathology, Antigen, Human papillomavirus infection, Health, Poster, RUO, Name, TSX, Review, Goal, Health Canada, MDX, GLOBE, Solution, News, COVID, FDA, Engineering, European, Infection, Vaccine, Neoplasm

At EUROGIN, Microbix will be exhibiting alongside leading diagnostics firms that provide screening-tests for detection of HPV infections.

Key Points: 
  • At EUROGIN, Microbix will be exhibiting alongside leading diagnostics firms that provide screening-tests for detection of HPV infections.
  • Microbix will also review performance of its multiplex high-risk HPV QAPs in supporting quality management of testing for high-risk types of HPV via full and extended genotyping assays.
  • Its poster presentation is titled Performance of full and extended genotyping assays using a new high-risk HPV multiplex panel.
  • A presentation titled Validation of MSwab medium for the elution of FLOQSwabs for human papillomavirus (HPV) detection on six commercial PCR-based HPV assays will demonstrate new self-sampling tools for HPV screening programs.

International Harrington Prize Jointly Awarded to Drs. James Crowe and Michel Nussenzweig

Retrieved on: 
星期四, 三月 24, 2022
University of Texas Southwestern Medical Center, AAP, National Cancer Institute, Mount Sinai Hospital, Cardiology, Rockefeller University, University, Johns Hopkins University, Biochemistry, LDL, Massachusetts General Hospital, Pediatrics, PCSK9, All India Mahila Congress, Harvard University, University Hospitals Cleveland Medical Center, Disorder, Biology, NIH, ASCI, Science, Degenerative disease, Thalassemia, Doctor of Philosophy, Disease, Severe acute respiratory syndrome coronavirus 2, Marfan syndrome, Diabetes, Society, COVID, Patient, Creativity, Antibody, Human, Academic health science centre, Microbiology, University of Pennsylvania, Pathology, CAR, Immunology, Human papillomavirus infection, COVID-19, Sickle cell disease, Northwestern Medicine, HHMI, Division, Pharmaceutical industry, Vaccine, MD, Medicine

CLEVELAND, March 24, 2022 /PRNewswire/ -- The ninth annual Harrington Prize for Innovation in Medicine has been jointly awarded to James E. Crowe, Jr., MD, Director, Vanderbilt Vaccine Center and Professor, Departments of Pediatrics and Pathology, Microbiology and Immunology, Vanderbilt School of Medicine, and Michel C. Nussenzweig, MD, PhD, Investigator, HHMI, and Zanvil A. Cohn and Ralph M. Steinman Professor, The Rockefeller University. The award recognizes their groundbreaking work, which has elucidated fundamental principles of the human immune response and enabled the use of human antibodies to treat COVID-19.

Key Points: 
  • Dr. Crowe has advanced the discovery of human monoclonal antibodies for many of the most pathogenic viruses that cause human disease.
  • Dr. Nussenzweig showed that antibodies cloned directly from humans can be a safe and effective treatment against viral infections when passively transferred to other humans.
  • A committee composed of members of the ASCI Council and the Harrington Discovery Institute Scientific Advisory Board reviewed nominations from leading academic medical centers from eight countries before selecting the 2022 Harrington Prize recipients.
  • Crowe and Nussenzweig are extraordinary physician-scientists who took distinct and separate paths but arrived at the same endpoint.

Emblation Announces Agreement with Specialist Medical Organisation Bo Medical for Exclusive Distribution of Swift® in the Netherlands, Belgium, and Luxembourg

Retrieved on: 
星期一, 三月 14, 2022
Aesthetics, Podiatry, HPV, Adoption, Wart, Internet, Hospital, Skin, Human papillomavirus infection, Patient, Technology, Invention, Medicine, Microwave, Pharmaceutical industry, Medical imaging, Healthcare, Swift, Dermatology, Benelux

EDINBURGH, Scotland, March 14, 2022 /PRNewswire-PRWeb/ --Emblation Limited, the global leader in medical microwave technology, is delighted to announce an agreement with Bo Medical, a specialist distributor of medical and aesthetic devices and products, for the exclusive distribution of Swift microwave therapy.

Key Points: 
  • EDINBURGH, Scotland, March 14, 2022 /PRNewswire-PRWeb/ --Emblation Limited, the global leader in medical microwave technology, is delighted to announce an agreement with Bo Medical, a specialist distributor of medical and aesthetic devices and products, for the exclusive distribution of Swift microwave therapy.
  • Alongside Calista Medical in Switzerland, the agreement with Bo Medical, based in the Netherlands, signals the launch of Swift in mainland Europe.
  • With treatment times in seconds, Swift provides Dermatologists and Podiatrists with a new, precise, and effective procedure for benign skin lesions.
  • Jonathan Williamson, Chief Commercial Officer of Emblation, commented, "We are really looking forward to launching Swift with Bo Medical.

SQZ Biotechnologies to Present New Enhanced APC Platform Preclinical Findings and ENVOY-001 Phase 1/2 Clinical Trial in Progress Poster at the American Association for Cancer Research 2022 Annual Meeting

Retrieved on: 
星期二, 三月 8, 2022
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Virus, City of Hope National Medical Center, Immune tolerance, EAPC, AACR, Clinical trial, American Association for Cancer Research, Red blood cell, Infection, Center, RNA transfection, Private Securities Litigation Reform Act, City, Human papillomavirus infection, IND, Research, APC, AAC, Therapy, FDA, Confidentiality, Publication, Annual report, Penis, U.S. Securities and Exchange Commission, Cancer, Centers for Disease Control and Prevention timeline, HPV, CD86, SQZ, Woman, Antigen, Degenerative disease, Risk, Cell, NYSE, CDC, Monocyte, CD8, Patient, Canadian International Council, American Association, Â, Man, AACS, COVID-19, NK, Association, Vulva, Travel, Adaptive clinical trial, Vaccine, Pharmaceutical industry, Cytomegalovirus, SQZ-eAPC-HPV, SQZ-AAC-HPV, Human Papillomavirus Positive Cancers, SQZ Biotechnologies, SQZ-EAPC-HPV, SQZ-AAC-HPV, HUMAN PAPILLOMAVIRUS POSITIVE CANCERS, SQZ BIOTECHNOLOGIES

In January, the FDA gave IND clearance for SQZ-eAPC-HPV, the companys first eAPC therapeutic candidate, for use in patients who have HPV16+ solid tumors.

Key Points: 
  • In January, the FDA gave IND clearance for SQZ-eAPC-HPV, the companys first eAPC therapeutic candidate, for use in patients who have HPV16+ solid tumors.
  • SQZ eAPCs are intended to build on the promising preliminary monotherapy results from our SQZ APC candidate by expanding the addressable patient population and directly incorporating combination-like functionality.
  • In addition to the new eAPC preclinincal data, a Trial in Progress poster presentation of the ENVOY-001 Phase 1/2 clinical trial will be delivered by Victoria Villaflor, M.D., City of Hope Medical Center.
  • Human papillomavirus (HPV) is one of the most common viruses worldwide and certain strains persist for many years leading to cancer.

Worldwide Oral Cancer Treatment Industry to 2030 - Featuring Cipla, Sanofi and Teva Pharmaceuticals Industries Among Others - ResearchAndMarkets.com

Retrieved on: 
星期四, 三月 3, 2022
Pharmaceutical, Health, Oncology, Oral, Oral cancer, Recurrence, Death, Immunotherapy, Treatment, Woman, Prevalence, Risk, Mouth, Awareness, Human papillomavirus infection, Growth, Head, Man, Disease, Profile, Smokeless tobacco, National Cancer Institute, Exocrine gland, Squamous cell carcinoma, CAGR, Tongue, Malignancy, Oropharyngeal cancer, National, Neoplasm, Dentistry, Birth control

The global oral cancer treatment market was valued at $ 1,710.53 million 2020, and is projected to reach $ 2,729.72 Million by 2030 registering a CAGR of 4.80% from 2021 to 2030.

Key Points: 
  • The global oral cancer treatment market was valued at $ 1,710.53 million 2020, and is projected to reach $ 2,729.72 Million by 2030 registering a CAGR of 4.80% from 2021 to 2030.
  • Oral cancer is a type of head and neck cancer that manifests itself in the mouth as a tumor.
  • Furthermore, according to the Oral Cancer Foundation, every year around 53,000 new oral cancer cases are diagnosed and more than 9,750 people succumb to the disease in the U.S.
  • The oral cancer treatment market is segmented on the basis of treatment, age group, end user, and region.

St. Jude creates HPV cancer prevention awareness campaign to emphasize the need for HPV vaccination

Retrieved on: 
星期五, 三月 4, 2022
People, Social media, Woman, Korea Disease Control and Prevention Agency, National Cancer Institute (Egypt), Hospital, International, List, Vaccination, Awareness, Solution, NCI-designated Cancer Center, Survival, Multimedia, Cancer, Man, St. Jude Children's Research Hospital, National Cancer Institute, Human papillomavirus infection, CEO, Parent, HPV, Child, CDC, Center, Survivor, Southeastern United States, Vaccine, Jude the Apostle

MEMPHIS, Tenn., March 4, 2022 /PRNewswire/ -- The St. Jude Children's Research Hospital HPV Cancer Prevention Program today launched a public awareness campaignto bring more attention to the need for and benefits of adolescents ages 9-12 receiving on-time human papillomavirus (HPV) vaccination to prevent cancer.

Key Points: 
  • MEMPHIS, Tenn., March 4, 2022 /PRNewswire/ -- The St. Jude Children's Research Hospital HPV Cancer Prevention Program today launched a public awareness campaignto bring more attention to the need for and benefits of adolescents ages 9-12 receiving on-time human papillomavirus (HPV) vaccination to prevent cancer.
  • "St. Jude has been actively engaged over the past several years in raising awareness about HPV.
  • "In honor of International HPV Awareness Day, join us to help create a future free of HPV."
  • "Together, with our campaign partners, we hope to increase awareness of the benefits of on-time HPV vaccination for cancer prevention and provide tangible resources to help peers working in community and health care settings to better meet people where they are," said Heather Brandt , Ph.D., St. Jude HPV Cancer Prevention Program director.